Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy

European Journal of Cancer

Volumn 46, Issue 12, 2010, Pages 2225-2234

  Grønberg, Bjørn H ^a,b   Sundstrøm, Stein ^a,b   Kaasa, Stein ^a,b   Bremnes, Roy M ^c,d   Fløtten, Øystein ^e   Amundsen, Tore ^a,b   Hjelde, Harald H ^b   Plessen, Christian Von ^e,f   Jordhøy, Marit ^g,h  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF BERGEN   (Norway)

^g INNLANDET HOSPITAL TRUST   (Norway)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Carboplatin; Gemcitabine; Neutropenic infection; Pemetrexed; Predictive factors; Prognostic factors; Treatment outcome

Indexed keywords

CARBOPLATIN; GEMCITABINE; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; BONE MARROW; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DRUG TOLERANCE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; KIDNEY FUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERFORMANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; QUALITY OF LIFE; QUESTIONNAIRES; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 77955712442     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.04.009     Document Type: Article

References (30)

1. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25.
2. D.G. Pfister, D.H. Johnson, and C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
3. K. Lang, M.D. Marciniak, and D. Faries Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States Lung Cancer 63 2009 264 270
4. C.J. Sweeney, J. Zhu, and A.B. Sandler Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma Cancer 92 2001 2639 2647
5. J. Vardy, R. Dadasovich, and P. Beale Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials BMC Cancer 9 2009 130
6. L. Talarico, G. Chen, and R. Pazdur Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US food and drug administration J Clin Oncol 22 2004 4626 4631
7. M.L. Janssen-Heijnen, R.M. Schipper, and P.P. Razenberg Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study Lung cancer 21 1998 105 113
8. Cancer Registry of Norway. Cancer in Norway 2007 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2008.
9. S. Firat, M. Bousamra, and E. Gore Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 52 2002 1047 1057
10. S. Firat, R.W. Byhardt, and E. Gore Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 54 2002 357 364
11. M. Extermann Measurement and impact of comorbidity in older cancer patients Crit Rev Oncol Hematol 35 2000 181 200
12. W.L. Read, R.M. Tierney, and N.C. Page Differential prognostic impact of comorbidity J Clin Oncol 22 2004 3099 3103
13. T.R. Asmis, K. Ding, and L. Seymour Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials J Clin Oncol 26 2008 54 59
14. W. Jacot, B. Colinet, and D. Bertrand Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients Ann Oncol 19 2008 1458 1464
15. P. Maione, F. Perrone, and C. Gallo Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study J Clin Oncol 23 2005 6865 6872
16. L. Moscetti, F. Nelli, and D. Padalino Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome J Chemother 17 2005 685 692
17. R. Marinello, D. Marenco, and D. Roglia Predictors of treatment failures during chemotherapy: a prospective study on 110 older cancer patients Arch Gerontol Geriatr 48 2009 222 226
18. Grønberg BH, Bremnes RM, Fløtten Ø, et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, in press.
19. B.S. Linn, M.W. Linn, and L. Gurel Cumulative illness rating scale J Am Geriatr Soc 16 1968 622 626
20. Miller MD, Towers A. A manual for guidelines for scoring the cumulative illness rating scale for geriatrics (CIRS-G). University of Pittsburgh, May 1991.
21. M. Extermann Measuring comorbidity in older cancer patients Eur J Cancer 36 2000 453 471
22. D.M. Finkelstein, D.S. Ettinger, and J.C. Ruckdeschel Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study J Clin Oncol 4 1986 702 709
23. P. Goldstraw, J. Crowley, and K. Chansky The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours J Thorac Oncol 2 2007 706 714
24. H.A. Wakelee, W. Wang, and J.H. Schiller Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594 J Thorac Oncol 1 2006 441 446
25. C.M. Tammemagi, C. Neslund-Dudas, and M. Simoff Smoking and lung cancer survival: the role of comorbidity and treatment Chest 125 2004 27 37
26. S. Sundstrom, R.M. Bremnes, and P. Brunsvig Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? J Thorac Oncol 1 2006 816 824
27. D. Osoba, A. Bezjak, and M. Brundage Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group Eur J Cancer 41 2005 280 287
28. J.A. Talcott, R. Finberg, and R.J. Mayer The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation Arch Intern Med 148 1988 2561 2568
29. J. Klastersky, M. Paesmans, and E.B. Rubenstein The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients J Clin Oncol 18 2000 3038 3051
30. N.B. Oozeer, J. Benbow, and C. Downs The effect of comorbidity on quality of life during radiotherapy in head and neck cancer Otolaryngol Head Neck Surg 139 2008 268 272